Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus

European Journal of Pharmacology

Volumn 500, Issue 1-3 SPEC. ISS., 2004, Pages 467-485

  Couture, Réjean ^a   Girolami, Jean Pierre ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHU RANGUEIL   (France)

Author keywords

Angiotensin 1 converting enzyme; Bradykinin; Diabetes mellitus; Kinin B 1 receptor; Kinin B 2 receptor; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; KALLIKREIN; KININ; KININ BETA1 RECEPTOR; KININ BETA2 RECEPTOR; NITRIC OXIDE; PROSTACYCLIN; RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG;

BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR FUNCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM LESION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENETIC MARKER; GLUCOSE TRANSPORT; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KALLIKREIN KININ SYSTEM; KIDNEY; LYMPHOCYTIC INFILTRATION; MITOSIS INHIBITION; MOLECULAR INTERACTION; OUTCOMES RESEARCH; OXIDATIVE STRESS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR SENSITIVITY; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; KININS; OXIDATIVE STRESS; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

EID: 4644337419     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.045     Document Type: Review

References (243)

1. 2-receptor-null mice Hypertension 42 2003 600 604
2. 1 receptors in retinal microvessels of the streptozotocin-diabetic rat Br. J. Pharmacol. 140 1 2003 33 40
3. L.M. Aiello Perspectives on diabetic retinopathy Am. J. Ophthalmol. 136 1 2003 122 135
4. 2 receptors Hypertension 29 1997 483 487
5. C. Alric, C. Pecher, J.-L. Bascands, and J.-P. Girolami Effect of bradykinin on tyrosine kinase and phosphatase activities and cell proliferation in mesangial cells Immunopharmacology 45 1-3 1999 57 62
6. M. Amblard, I. Daffix, P. Bedos, G. Berge, D. Pruneau, J.L. Paquet, J.M. Luccarini, P. Bélichard, P. Dodey, and J. Martinez Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety J. Med. Chem. 42 20 1999 4185 4192
7. K. Asahi, K. Ichimori, H. Nakazawa, Y. Izuhara, R. Inagi, T. Watanabe, T. Miyata, and K. Kurokawa Nitric oxide inhibits the formation of advanced glycation end products Kidney Int. 58 4 2000 1780 1787
8. 2 receptor antagonist, FR165649, and agonist, FR190997 Br. J. Pharmacol. 124 3 1998 441 446
9. T. Baba, S. Murabayashi, T. Ishizaki, Y. Ido, K. Aoyagi, and K. Takebe Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy Diabetologia 29 3 1986 162 167
10. D.R. Bachvarov, J.F. Hess, J.G. Menke, J.F. Larrivée, and F. Marceau Structure and genomic organization of the human B1 receptor gene for kinins (BDKRB1) Genomics 33 1996 374 381
11. D.R. Bachvarov, M. Landry, I. Pelletier, M. Chevrette, C. Betard, I. Houde, J. Bergeron, M. Lebel, and F. Marceau Characterization of two polymorphic sites in the human kinin B1 receptor gene: altered frequency of an Allele in patients with a history of end-stage renal failure J. Am. Soc. Nephrol. 9 1998 598 604
12. N. Bank, M.A. Lahorra, H.S. Aynedjian, and D. Schlondorff Vasoregulatory hormones and the hyperfiltration of diabetes Am. J. Physiol. 254 2 Pt2 1988 F202 F209
13. J.-L. Bascands, J.P. Schanstra, R. Couture, and J.-P. Girolami Les récepteurs de la bradykinine: de nouveaux rôles physio-pathologiques Médecine/Sciences 19 11 2003 1093 1100
14. J.W. Baynes Role of oxidative stress in development of complications in diabetes Diabetes 40 1991 405 412
15. N. Begum, H.M. Tepperman, and J. Tepperman Studies on the possible involvement of prostaglandins in insulin generation of pyruvate dehydrogenase activator Diabetes 34 1 1985 29 37
16. 2 receptor stimulation in conscious instrumented dogs Br. J. Pharmacol. 117 7 1996 1565 1571
17. S.J. Benbow, and I.A. MacFarlane Painful diabetic neuropathy Baillière's Clin. Endocrinol. Metab. 13 2 1999 295 308
18. 2 kinin receptor within the plasma membrane of native endothelial cells Circulation 99 1999 2034 2040
19. K.D. Bhoola, C.D. Figueroa, and K. Worthy Bioregulation of kinins: kallikreins, kininogens, and kininases Pharmacol. Rev. 44 1992 1 80
20. C. Blais Jr., J.L. Rouleau, N.J. Brown, Y. Lepage, D. Spence, C. Munoz, J. Friborg, D. Geadah, N. Gervais, and A. Adam Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema Immunopharmacology 43 2-3 1999 293 302
21. C.Jr. Blais, D. Fortin, J.L. Rouleau, G. Molinaro, and A. Adam Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts J. Pharmacol. Exp. Ther. 295 2 2000 621 626
22. A. Blaukat Structure and signalling pathways of kinin receptors Andrologia 35 1 2003 17 23
23. I. Brochu, J. Labonté, G. Bkaily, and P. D'Orléans-Juste Role of endothelin receptors in the hypertensive state of kinin B2 knockout mice subjected to a high-salt diet Clin. Sci. 103 Suppl. 48 2002 380S 384S
24. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 6865 2001 813 820
25. H. Cai, K.K. Griendling, and D.G. Harrison The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases Trends Pharmacol. Sci. 24 9 2003 471 478
26. N.E. Cameron, S.E. Eaton, M.A. Cotter, and S. Tesfaye Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy Diabetologia 44 2001 1973 1988
27. D.J. Campbell Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides Braz. J. Med. Biol. Res. 33 2000 665 677
28. M.M. Campos, G.E.P. Souza, and J.B. Calixto In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor κB pathways Br. J. Pharmacol. 127 1999 1851 1859
29. M.M. Campos, D.A. Cabrini, A.H. Cardozo, G.A. Rae, J.H. Toro, and J.B. Calixto Changes in paw oedema triggered via bradykinin B(1) and B(2) receptors in streptozotocin-diabetic rats Eur. J. Pharmacol. 416 1-2 2001 169 177
30. C.R.O. Carvalho, A.C.P. Thirone, J.A.R. Gontijo, L.A. Velloso, and M.J.A. Saad Effect of captopril, losartan, and bradykinin on early steps of insulin action Diabetes 46 1997 1950 1957
31. 2 receptor activation reduces Erk1 and Erk2 phosphorylation induced by insulin-like growth factor-1, platelet-derived growth factor-BB, and high glucose in rat isolated glomeruli Can. J. Physiol. Pharm. 80 2002 341 345
32. E. Cellier, M. Mage, J. Duchêne, C. Pécher, R. Couture, J.-L. Bascands, and J.P. Girolami Bradykinin reduces growth factor-induced glomerular ERK1/2 phosphorylation Am. J. Physiol. Renal Physiol. 284 2003 F282 F292
33. A. Ceriello Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications Diabetes Nutr. Metab. 12 1999 42 46
34. 2 receptor null mice Hypertension 34 1999 176 180
35. 2 receptor knockout mice Hypertension 37 3 2001 967 973
36. 1 receptor Br. J. Pharmacol. 108 2 1993 318 322
37. J. Chao, J.J. Zhang, K.F. Lin, and L. Chao Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats Hum. Gene Ther. 9 1998 21 31
38. Y. Christen, B. Waeber, J. Nussberger, M. Porchet, R.M. Borland, R.J. Lee, K. Maggon, L. Shum, P.B. Timmermans, and H.R. Brunner Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II Circulation 83 4 1991 1333 1342
39. 2-kinin receptors by glucose in vascular smooth muscle cells. Am J. Physiol. Heart Circ. Physiol. 280 4 2001 H1537 H1546
40. 2 receptor agonists in the spinal cord of streptozotocin-diabetic rats Br. J. Pharmacol. 130 2000 375 385
41. M.E. Cooper Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy Diabetologia 44 11 2001 1957 1972
42. R. Couture, and C.J. Lindsey Brain kallikrein-kinin system: from receptors to neuronal pathways and physiological functions R. Quirion A. Björklund T. Hökfelt Handbook of Chemical Neuroanatomy Peptide Receptors, Part I vol. 16 2000 Elsevier Science B.V. Amsterdam, The Netherlands 241 300
43. R. Couture, M. Harrisson, R.M. Vianna, and F. Cloutier Kinin receptors in pain and inflammation Eur. J. Pharmacol. 429 2001 161 176
44. J. Damas, V. Bourdon, and P.J. Lefebvre Insulin sensitivity, clearance and release in kininogen-deficient rats Exp. Physiol. 84 3 1999 549 557
45. B.J. Davis, J.M. Forbes, M.C. Thomas, G. Jerums, W.C. Burns, H. Kawachi, T.J. Allen, and M.E. Cooper Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat Diabetologia 47 2004 89 97
46. D. deBlois, and R.A. Horlick Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects Br. J. Pharmacol. 132 1 2001 327 335
47. E.M. de Cavanagh, C.G. Fraga, L. Ferder, and F. Inserra Enalapril and captopril enhance antioxidant defenses in mouse tissues Am. J. Physiol. 272 2 Pt2 1997 R514 R518
48. E.M. de Cavanagh, L. Ferder, F. Carrasquedo, D. Scrivo, A. Wassermann, C.G. Fraga, and F. Inserra Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients Am. J. Kidney Dis. 34 3 1999 445 455
49. E.M. de Cavanagh, F. Inserra, J. Tobli, I. Stella, C.G. Fraga, and L. Ferder Enalapril attenuates oxidative stress in diabetic rats Hypertension 38 5 2001 1130 1136
50. A. Dendorfer, S. Reissmann, S. Wolfrum, W. Raasch, and P. Dominiak Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation Hypertension 38 2001 142 146
51. A.S. De Vriese, T.J. Verbeuren, J. Van de Voorde, N.H. Lameire, and P.M. Vanhoutte Endothelial dysfunction in diabetes Br. J. Pharmacol. 130 5 2000 963 974
52. S.S. Dhamrait, J.R. Payne, P. Li, A. Jones, I.S. Toor, J.A. Cooper, E. Hawe, J.M. Palmen, P.T.E. Wootton, G.J. Miller, S.E. Humphries, and H.E. Montgomery Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension Eur. Heart J. 24 2003 1672 1680
53. P.J. Dickinson, A.L. Carrington, G.S. Frost, and A.J.M. Boulton Neurovascular disease, antioxidants and glycation in diabetes Diabetes Metab. Res. Rev. 18 2002 260 272
54. G. Dietze, E. Maerker, C. Lodri, R. Schifman, M. Wicklmayr, R. Geiger, E. Fink, I. Boettger, H. Fritz, and H. Mehnert Possible involvement of kinins in muscle energy metabolism Adv. Exp. Med. Biol. 167 1984 63 71
55. G.J. Dietze, M. Wicklmayr, K. Rett, S. Jacob, and E.J. Henriksen Potential role of bradykinin in forearm muscle metabolism in humans Diabetes 45 Suppl. 1 1996 S110 S114
56. M. Donoghue, F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, N. Stagliano, M. Donovan, B. Woolf, K. Robison, R. Jeyaseelan, R.E. Breitbart, and S. Acton A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circ. Res. 87 5 2000 E1 E9
57. 1 receptors for kinins J. Pharmacol. Exp. Ther. 259 3 1991 997 1003
58. 2 de la bradykinine: voie alternative et antiproliférative Néphrologie 23 1 2002 39 41
59. J. Duchêne, J.P. Schanstra, C. Pecher, A. Pizard, C. Susini, J.-P. Esteve, J.-L. Bascands, and J.P. Girolami A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation J. Biol. Chem. 277 43 2002 40375 40383
60. 1 receptor Br. J. Pharmacol. 141 4 2004 728 736
61. 2 receptor of bradykinin in insulin sensitivity Hypertension 38 2001 1355 1360
62. 1 receptors of bradykinin Hypertension 42 2003 1021 1025
63. L.V. d'Uscio, T. Quaschning, J.C. Burnett Jr., and T.F. Luscher Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition Hypertension 37 1 2001 28 33
64. C. Emanueli, and P. Madeddu Targeting kinin receptors for the treatment of tissue ischaemia Trends Pharmacol. Sci. 22 9 2001 478 484
65. 2 receptor gene Hypertension 31 1998 1278 1283
66. C. Emanueli, A. Zacheo, A. Minasi, J. Chao, L. Chao, M.B. Salis, T. Stacca, S. Straino, M.C. Capogrossi, and P. Madeddu Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle Arterioscler. Thromb. Vasc. Biol. 20 11 2000 2379 2385
67. C. Emanueli, A. Minasi, A. Zacheo, J. Chao, L. Chao, M.B. Salis, S. Straino, M.G. Tozzi, R. Smith, L. Gaspa, G. Bianchini, F. Stillo, M.C. Capogrossi, and P. Madeddu Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia Circulation 103 1 2001 125 132
68. C. Emanueli, M.B. Salis, A. Pinna, T. Stacca, A.F. Milia, A. Spano, J. Chao, L. Chao, L. Sciola, and P. Madeddu Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer Circulation 106 8 2002 993 999
69. 1 receptor for therapeutic neovascularization Circulation 105 2002 360 366
70. E.L. Feldman Oxidative stress and diabetic neuropathy: a new understanding of an old problem J. Clin. Invest. 111 2003 431 433
71. Y. Feng, T. Niu, X. Xu, C. Chen, Q. Li, R. Qian, G. Wang, and X. Xu Insertion/deletion polymorphism of the ACE gene is associated with type 2 diabetes Diabetes 51 2002 1986 1988
72. 2 receptors on skeletal muscle cells Diabetes 45 Suppl. 1 1996 24 28
73. J.M. Forbes, M.E. Cooper, V. Thallas, W.C. Burns, M.C. Thomas, G.C. Brammar, F. Lee, S.L. Grant, L.A. Burrell, G. Jerums, and T.M. Osicka Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy Diabetes 51 11 2002 3274 3282
74. M.A. Forgione, N. Weiss, S. Heydrick, A. Cap, E.S. Klings, C. Bierl, R.T. Eberhardt, H.W. Farber, and J. Loscalzo Cellular glutathione peroxidase deficiency and endothelial dysfunction Am. J. Physiol. Heart Circ. Physiol. 282 4 2002 H1255 H1261
75. 1 receptor? Am. J. Physiol. Heart Circ. Physiol. 285 2003 H277 H282
76. 1 receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice Eur. J. Pharmacol. 457 2002 115 124
77. 1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice Peptides 24 2003 1131 1139
78. 1 receptor antagonists inhibit diabetes-induced hyperalgesia in mice Neuropeptides 37 2003 36 44
79. B.H. Gabra, R. Couture, and P. Sirois Dualité fonctionnelle des récepteurs des kinines en physiopathologie Médecine/Sciences 19 11 2003 1101 1110
80. J.V. Gainer, N.J. Brown, M. Bachvarova, L. Bastien, I. Maltais, F. Marceau, and D.R. Bachvarov Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans Am. J. Hypertens. 13 2000 1268 1273
81. A.M. Gallagher, H. Yu, and M.P. Printz Bradykinin-induced reductions in collagen gene expression involve prostacylin Hypertension 32 1 1998 84 88
82. 2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin Can. J. Physiol. Pharm. 80 2002 151 161
83. P. Gohlke, C. Pees, and T. Unger AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism Hypertension 31 1 Pt2 1998 349 355
84. F.K. Gorus, I. Weets, P. Couck, and D.G. Pipeleers Epidemiology of type 1 and type 2 diabetes. The added value of diabetes registries for conducting clinical studies: the Belgian paradigm Acta Clin. Belg. 59 1 2004 1 13
85. 1 receptor. Biochemical and pharmacological characterization J. Pharmacol. Exp. Ther. 309 2 2004 661 669
86. A. Graness, S. Hanke, F.D. Boehmer, P. Presek, and C. Liebmann Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor-transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells Biochem. J. 347 2000 441 447
87. G. Grassi Diabetic retinopathy Minerva Med. 94 6 2003 419 435
88. K.K. Griendling, and G.A. FitzGerald Oxidative stress and cardiovascular injury: Part I. Basic mechanisms and in vivo monitoring of ROS Circulation 108 16 2003 1912 1916
89. H. Ha, and K.H. Kim Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C Diabetes Res. Clin. Pract. 45 1999 147 151
90. H. Ha, S.H. Lee, and K.H. Kim Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-beta and fibronectin, and lipid peroxidation induced by high glucose in cultured mesangial cells J. Pharmacol. Exp. Ther. 281 3 1997 1457 1462
91. 1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide Br. J. Pharmacol. 140 5 2003 987 995
92. C.W. Heilig, F.C. Brosius, and D.N. Henry Glucose transporters of the glomerulus and the implications for diabetic nephropathy Kidney Int. 52 Suppl. 60 1997 S-91 S-99
93. C.W. Heilig, J.I. Kreisberg, S. Freytag, T. Murakami, Y. Ebina, L. Guo, K. Heilig, R. Loberg, X. Qu, Y. Jin, D. Henry, and F.C. Brosius Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression Am. J. Physiol. Renal Physiol. 280 4 2001 F657 F666
94. H. Heitsch The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease Expert Opin. Investig. Drugs 12 5 2003 759 770
95. E.J. Henriksen, and S. Jacob Effect of captopril on glucose transport activity in skeletal muscle of obese Zucker rats Metabolism 44 1995 267 272
96. E.J. Henriksen, S. Jacob, H.J. Agustin, and G.J. Dietze Glucose transport activity in insulin resistant rat muscle: effects of ACE inhibitors and bradykinin antagonism Diabetes 45 Suppl. 1 1996 S125 S128
97. E.J. Henriksen, S. Jacob, D.L. Fogt, and G.J. Dietze Effects of chronic bradykinin administration on insulin action in an animal model of insulin resistance Am. J. Physiol. 275 1998 R40 R45
98. E.J. Henriksen, S. Jacob, T.R. Kinnick, E.B. Youngblood, M.B. Schmit, and G.J. Dietze ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide Am. J. Physiol. 277 1 Pt2 1999 R332 R336
99. A.D. Hodgkinson, T. Bartlett, P.J. Oates, B.A. Millward, and A.G. Demaine The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy Diabetes 52 3 2003 846 851
100. J. Himmelfarb, and E. McMonagle Albumin is the major plasma protein target of oxidant stress in uremia Kidney Int. 60 1 2001 358 363
101. 9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats Br. J. Pharmacol. 109 1 1993 14 17
102. W. Huang, Y. Gallois, N. Bouby, P. Bruneval, D. Heudes, M.-F. Belair, J.H. Krege, P. Meneton, M. Marre, O. Smithies, and F. Alhenc-Gelas Genetically increased angiotensin 1-converting enzyme level and renal complications in the diabetic mouse Proc. Natl. Acad. Sci. U. S. A. 98 2001 13330 13334
103. M.J. Hussain, M. Peakman, H. Gallati, S.S. Lo, M. Hawa, G.C. Viberti, P.J. Watkins, R.D. Leslie, and D. Vergani Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM Diabetologia 39 1 1996 60 69
104. 1 receptor by ACE inhibitors Int. Immunopharmacol. 2 13-14 2002 1787 1793
105. 1 receptor J. Biol. Chem. 277 19 2002 16847 16852
106. 2 receptor is required for full expression of renal COX-2 and renin Peptides 24 2003 1141 1147
107. S. Isami, H. Kishikawa, E. Araki, M. Uechara, K. Kaneko, T. Shirotani, M. Todaka, S. Ura, S. Motoyoshi, K. Matsumoto, N. Miyamura, and M. Shichiri Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway Diabetologia 39 4 1996 412 420
108. A.A. Jaffa, D.H. Miller, G.S. Bailey, J. Chao, H.S. Margolius, and R.K. Mayfield Abnormal regulation of renal kallikrein in experimental diabete effects of insulin on prokallikrein synthesis and activation J. Clin. Invest. 80 6 1987 1651 1659
109. A.A. Jaffa, K.X. Chai, J. Chao, L. Chao, and R.K. Mayfield Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney Kidney Int. 41 1992 789 795
110. A.A. Jaffa, P.F. Rust, and R.K. Mayfield Kinin, a mediator of diabetes-induced glomerular hyperfiltration Diabetes 44 2 1995 156 160
111. A.A. Jaffa, C. Vio, V. Velarde, D. LeRoith, and R.K. Mayfield Induction of renal kallikrein and renin gene expression by insulin and IGF-I in the diabetic rat Diabetes 46 12 1997 2049 2056
112. A.A. Jaffa, R. Durazo-Arvizu, D. Zheng, D.T. Lackland, S. Srikanth, W.T. Garvey, and A.H. Schmaier Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes Diabetes 52 5 2003 1215 1221
113. Z.Y. Jiang, Y.W. Lin, A. Clemont, E.P. Feener, K.D. Hein, M. Igarashi, T. Yamauchi, M.F. White, and G.L. King Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats J. Clin. Invest. 104 4 1999 447 457
114. H.S. Kim, J.H. Krege, K.D. Kluckman, J.R. Hagaman, J.B. Hodgin, C.F. Best, J.C. Jennette, T.M. Coffman, N. Maeda, and O. Smithies Genetic control of blood pressure and the angiotensinogen locus Proc. Natl. Acad. Sci. U. S. A. 92 1995 2735 2739
115. N.N. Kim, S. Villegas, S. Summerour, and F.J. Villarreal Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide J. Mol. Cell. Cardiol. 31 2 1999 457 466
116. R.H. King The role of glycation in the pathogenesis of diabetic polyneuropathy J. Clin. Pathol. Mol. Pathol. 54 2001 400 408
117. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 9 1998 1414 1431
118. S. Kinugawa, H. Post, P.M. Kaminski, X. Zhang, X. Xu, H. Huang, F.A. Recchia, M. Ochoa, M.S. Wolin, G. Kaley, and T.H. Hintze Coronary microvascular endothelial stunning after acute pressure overload in the conscious dog is caused by oxidant processes Circulation 108 2003 2934 2940
119. K. Kishi, N. Muromoto, Y. Nakaya, I. Miyata, A. Hagi, H. Hayashi, and Y. Ebina Bradykinin directly triggers GLUT4 translocation via an insulin independent pathway Diabetes 47 4 1998 550 558
120. M. Kitada, D. Koya, T. Sugimoto, M. Isono, S. Araki, A. Kashiwagi, and M. Haneda Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy Diabetes 52 10 2003 2603 2614
121. R. Klein Diabetic retinopathy Annu. Rev. Public Health 17 1996 137 158
122. H. Knigge, M. Bluthner, A. Bruntgens, H. Sator, and E. Ritz G(-699)/C polymorphism in the bradykinin-1 receptor gene in patients with renal failure Nephrol. Dial. Transplant. 15 5 2000 586 588
123. O. Kohlman Jr., F. Neves, A. de, M. Ginoza, A. Taveres, M.L. Cezareti, M.T. Zanella, A.B. Ribeiro, I. Gavras, and H. Gavras Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia Hypertension 25 1995 1003 1007
124. R. Komers, and M.E. Cooper Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins Am. J. Physiol. 268 4 Pt2 1995 F588 F594
125. A. Kuoppala, K.A. Lindstedt, J. Saarinen, P.T. Kovanen, and J.O. Kokkonen Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma Am. J. Physiol. Heart Circ. Physiol. 278 2000 H1069 H1074
126. S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, H. Sugino, H. Matsuura, K. Chayama, Y. Teranishi, O. Iba, K. Amano, and H. Matsubara Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis Hypertension 41 2003 99 107
127. 1-receptors after heat stress in the rat Immunopharmacology 48 2000 43 49
128. 1-receptor-induced hypotension in the anesthetized dog J. Cardiovasc. Pharmacol. 28 5 1996 645 650
129. 1 receptors induced by tissue injury J. Immunol. 160 1998 1419 1426
130. C. Lee, K. Miura, X. Liu, and J.L. Zweier Biphasic regulation of leukocyte superoxide generation by nitric oxide and peroxynitrite J. Biol. Chem. 275 50 2000 38965 38972
131. C.I. Lee, X. Liu, and J.L. Zweier Regulation of xanthine oxidase by nitric oxide and peroxynitrite J. Biol. Chem. 275 13 2000 9369 9376
132. 2-kinin receptors in the renal tubular and hemodynamic response to bradykinin Am. J. Physiol. 262 1992 R72 R76
133. 2-receptor gene Circulation 96 1997 3570 3578
134. R. Maestri, A.F. Milia, M.B. Salis, G. Graiani, C. Lagrasta, M. Monica, D. Corradi, C. Emanueli, and P. Madeddu Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice Hypertension 41 5 2003 1151 1155
135. 1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation Can. J. Physiol. Pharm. 80 2002 328 333
136. 2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients Can. J. Physiol. Pharm. 80 2002 323 327
137. 1 receptors for kinins Pharmacol. Rev. 50 3 1998 357 386
138. 2 receptor expression in the rabbit Am. J. Physiol. 277 6 Pt 2 1999 R1568 R1578
139. B.M. Marcic, and E.G. Erdös Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin J. Pharmacol. Exp. Ther. 294 2000 605 612
140. 2 receptor Hypertension 33 1999 835 843
141. M.E. Marin-Castano, J.P. Schanstra, E. Neau, F. Praddaude, C. Pecher, J.L. Ader, J.P. Girolami, and J.L. Bascands Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin- converting enzyme inhibitor treatment Circulation 105 5 2002 627 632
142. R.K. Mayfield, H.S. Margolius, J.H. Levine, H.J. Wohltmann, C.B. Loadholt, and J.A. Colwell Urinary kallikrein excretion in insulin-dependent diabetes-mellitus and its relationship to glycemic control J. Clin. Endocrinol. Metab. 59 2 1984 278 286
143. M.F. McCarty ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes Med. Hypotheses 60 6 2003 779 783
144. S.I. McFarlane, A. Kumar, and J.R. Sowers Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease Am. J. Cardiol. 91 2003 30H 37H
145. P. Meneton, M. Bloch-Faure, A.A. Hagege, H. Ruetten, W. Huang, S. Bergaya, D. Ceiler, D. Gehring, I. Martins, G. Salmon, C.M. Boulanger, J. Nussberger, B. Crozatier, J.-M. Gasc, D. Heudes, P. Bruneval, T. Doetschman, J. Ménard, and F. Alhenc-Gelas Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice Proc. Natl. Acad. Sci. U. S. A. 98 5 2001 2634 2639
146. K. Mikrut, J. Paluszak, J. Kólik, P. Sosnowski, H. Krauss, and E. Grzékowiak The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia Diabetes Res. Clin. Pract. 51 2001 79 85
147. 2 receptor in dog skeletal muscle and rat L6 myoblasts Eur. J. Endocrinol. 138 1998 344 352
148. T. Miyata, C. van Ypersele de Strihou, Y. Ueda, K. Ichimori, R. Inagi, H. Onogi, N. Ishikawa, M. Nangaku, and K. Kurokawa Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms J. Am. Soc. Nephrol. 13 10 2002 2478 2487
149. T. Miyata, and C. van Ypersele de Strihou Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation Arch. Biochem. Biophys. 419 1 2003 50 54
150. 9-bradykinin J. Pharmacol. Exp. Ther. 303 1 2002 232 237
151. L. Morbidelli, A. Parenti, L. Giovannelli, H.J. Granger, F. Ledda, and M. Ziche B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects Br. J. Pharmacol. 124 6 1998 1286 1292
152. 2 bradykinin receptor gene is associated with essential hypertension Jpn. Circ. J. 63 1999 759 762
153. T. Münzel, and J.F. Keaney Are ACE inhibitors a «magic bullet» against oxidative stress? Circulation 104 2001 1571 1574
154. 2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs Br. J. Pharmacol. 110 1 1993 71 76
155. M. Nangaku, T. Miyata, T. Sada, M. Mizuno, R. Inagi, Y. Ueda, N. Ishikawa, H. Yuzawa, H. Koike, C. van Ypersele de Strihou, and K. Kurokawa Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model J. Am. Soc. Nephrol. 14 5 2003 1212 1222
156. 1 receptor gene in inflammation J. Biol. Chem. 273 1998 2784 2791
157. 9-bradykinin and susceptibility to inflammation J. Biol. Chem. 278 1 2003 219 225
158. 1 hypotensive receptors in rats by lipopolysaccharide Can. J. Physiol. Pharm. 74 3 1996 337 340
159. 1- receptor mediating hypotensive response in young brown Norway rats Immunopharmacology 33 1-3 1996 101 103
160. B. Ongali, H. Buck, S. de, F. Cloutier, F. Legault, D. Regoli, C. Lambert, G. Thibault, and R. Couture Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord Am. J. Physiol. Heart Circ. Physiol. 284 6 2003 H1949 H1958
161. 1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway FASEB J. 15 2001 1487 1489
162. I.Z. Pawluczyk, S.R. Patel, and K.P. Harris The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells Kidney Int. 65 4 2004 1240 1251
163. T. Pelikanova, P. Pinsker, I. Smrckova, L. Stribrna, and M. Dryakova Decreased urinary kallikrein with hyperglycemia in patients with short-term insulin-dependent diabetes mellitus J. Diabetes Its Complicat. 12 5 1998 264 272
164. J.B. Pesquero, R.C. Araujo, P.A. Heppenstall, C.L. Stucky, J.A.Jr. Silva, T. Walther, S.M. Oliveira, J.L. Pesquero, A.C. Paiva, J.B. Calixto, G.R. Lewin, and M. Bader Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors Proc. Natl. Acad. Sci. U. S. A. 97 14 2000 8140 8145
165. 1 receptors J. Cell. Physiol. 193 2002 275 286
166. A. Rabinovitch An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus Diabetes Metab. Rev. 14 2 1998 129 151
167. A. Rabinovitch, and W.L. Suarez-Pinzon Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus Biochem. Pharmacol. 55 8 1998 1139 1149
168. 2 receptors on skeletal muscle are coupled to inositol 1,4,5,-trisphosphate formation Diabetes 45 Suppl. 1 1996 29 33
169. D.M. Raidoo, R. Ramsaroop, S. Naidoo, W. Müller-Esterl, and K.D. Bhoola Kinin receptors in human vascular tissue: their role in atheromatous disease Immunopharmacology 36 2-3 1997 153 160
170. 1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus Ital. Heart J. 4 Suppl. 3 2003 210 216
171. 1- receptors for kinins in the rabbit by a bacterial lipopolysaccharide Eur. J. Pharmacol. 71 1 1981 105 115
172. D. Regoli, A. Rizzi, S.I. Perron, and F. Gobeil Classification of kinin receptors Biol. Chem. 382 2001 31 35
173. K. Rett, M. Wicklmayr, and G.J. Dietze Metabolic effects of kinins: historical and recent developments J. Cardiovasc. Pharmacol. 15 Suppl. 6 1990 S57 S59
174. K. Rett, M. Wicklmayr, G.J. Dietze, and H.U. Haring Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin Diabetes 45 Suppl. 1 1996 S66 S69
175. B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, and F. Soubrier An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J. Clin. Invest. 86 4 1990 1343 1346
176. R.H. Ritchie, R.J. Schiebinger, M.C. Lapointe, and J.D. Marsh Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide Am. J. Physiol. 275 4 Pt 2 1998 H1370 H1374
177. A. Rojas, S. Romay, D. Gonzalez, B. Herrera, R. Delgado, and K. Otero Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation and products Circ. Res. 86 3 2000 E50 E54
178. A.C. Rosenkranz, G.J. Dusting, and R.H. Ritchie Endothelial dysfunction limits the antihypertrophic action of bradykinin in rat cardiomycytes J. Mol. Cell. Cardiol. 32 6 2000 1119 1126
179. A.C. Rosenkranz, S.G. Hood, R.L. Woods, G.J. Dusting, and R.H. Ritchie B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP Diabetes 52 9 2003 2389 2395
180. A.M. Rothschild, V.L. Melo, M.L. Reis, M.C. Foss, and L. Gallo Jr. Kininogen and prekallikrein increases in the blood of streptozotocin-diabetic rats are normalized by insulin in vivo and in vitro Naunyn-Schmiedeberg's Arch. Pharmacol. 360 2 1999 217 220
181. J.L. Rouleau, M.A. Pfeffer, D.J. Stewart, D. Isaac, F. Sestier, E.K. Kerut, C.B. Porter, G. Proulx, C. Qian, and A.J. Block Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial Lancet 356 9230 2000 615 620
182. S.P. Sardi, F.M. Daray, A.E. Errasti, F.G. Pelorosso, V.A. Pujol-Lereis, V. Rey-Ares, M.P. Rogines-Velo, and R.P. Rothlin Further pharmacological characterization of bradykinin B1 receptor up-regulation in human umbilical vein J. Pharmacol. Exp. Ther. 290 1999 1019 1025
183. S. Schäfer, W. Linz, H. Vollert, G. Biemer-Daub, H. Rütten, M. Bleich, and A.E. Busch The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy Diabetologia 47 2004 98 103
184. S. Schäfer, K. Steioff, W. Linz, M. Bleich, A.E. Busch, and M. Lö;hn Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction Eur. J. Pharmacol. 484 2004 361 362
185. 1-receptor in cultured human lung fibroblasts J. Clin. Invest. 101 1998 2080 2091
186. 2 receptor activation reduces renal fibrosis J. Clin. Invest. 110 2002 371 379
187. 2 receptor activation Thromb. Haemost. 89 4 2003 735 740
188. 2 receptor Am. J. Physiol. Heart Circ. Physiol. 284 6 2003 H1904 H1908
189. 1 receptor blockade J. Am. Coll. Cardiol. 42 5 2003 911 913
190. A. Schmid, S. Eich-Rathfelder, E.T. Whalley, J.C. Cheronis, H.P. Scheuber, H. Fritz, and M. Siebeck Endogenous B1 receptor mediated hypotension produced by contact system activation in the presence of endotoxemia Immunopharmacology 40 2 1998 131 137
191. R.R. Shankar, Y. Wu, H.Q. Shen, J.S. Zhu, and A.D. Baron Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance Diabetes 49 2000 684 687
192. T. Shiuchi, T.-X. Cui, L. Wu, H. Nakagami, Y. Takeda-Matsubara, M. Iwai, and M. Horiuchi ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO Hypertension 40 2002 329 334
193. B. Simard, B.H. Gabra, and P. Sirois Inhibitory effect of a novel bradykinin B1 receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice Can. J. Physiol. Pharm. 80 2002 1203 1207
194. R. Singh, A. Barden, T. Mori, and L. Beilin Advanced glycation end-products: a review Diabetelogia 44 2001 129 146
195. J.R. Singleton, A.G. Smith, J.W. Russell, and E.L. Feldman Microvascular complications of impaired glucose tolerance Diabetes 52 2003 2867 2873
196. 2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat Br. J. Pharmacol. 141 5 2004 860 866
197. A. Solini, M.D. Vestra, A. Saller, R. Nosadini, G. Crepaldi, and P. Fioretto The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes Diabetes 51 2002 251 255
198. 2 receptor-mediated hypotension J. Hum. Hypertens., Suppl. 1 2000 S40 S46
199. J.M. Stewart Bradykinin antagonists: discovery and development Peptides 25 2004 527 532
200. J.B. Su, R. Houel, F. Heloire, F. Barbe, F. Beverelli, L. Sambin, A. Castaigne, A. Berdeaux, B. Crozatier, and L. Hittinger Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation Circulation 101 15 2000 1848 1853
201. D. Suzuki, T. Miyata, N. Saotome, K. Horie, R. Inagi, Y. Yasuda, K. Uchida, Y. Izuhara, M. Yagame, H. Sakai, and K. Kurokawa Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions J. Am. Soc. Nephrol. 10 4 1999 822 832
202. Y. Sawada, H. Kayakiri, Y. Abe, T. Mizutani, N. Inamura, M. Asano, C. Hatori, I. Aramori, T. Oku, and H. Tanaka Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks J. Med. Chem. 47 11 2004 2853 2863
203. Y. Sawada, H. Kayakiri, Y. Abe, T. Mizutani, N. Inamura, M. Asano, I. Aramori, C. Hatori, T. Oku, and H. Tanaka A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile J. Med. Chem. 47 10 2004 2667 2677
204. Y. Tan, F.N. Hutchison, and A.A. Jaffa Mechanisms of angiotensin II-induced expression of B2 kinin receptors Am. J. Physiol. Heart Circ. Physiol. 286 3 2004 H926 H932
205. N. Tanji, G.S. Markowitz, C. Fu, T. Kislinger, A. Taguchi, M. Pischetsrieder, D. Stern, A.M. Schmidt, and V.D. D'Agati Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease J. Am. Soc. Nephrol. 11 9 2000 1656 1666
206. B. Tesfamariam Free radicals in diabetic endothelial cell dysfunction Free Radic. Biol. Med. 16 3 1994 383 391
207. C. Tikellis, C.I. Johnston, J.M. Forbes, W.C. Burns, L.M. Burrell, J. Risvanis, and M.E. Cooper Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy Hypertension 41 3 2003 392 397
208. B. Tom, A. Dendorfer, R. de Vries, P.R. Saxena, and A.H.J. Danser Bradykinin potentiation by ACE inhibitors: a matter of metabolism Br. J. Pharmacol. 137 2002 276 284
209. B. Tom, A. Dendorfer, and A.H. Jan Danser Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int. J. Biochem. Cell Biol. 35 2003 792 801
210. H. Tomiyama, T. Kushiro, H. Abeta, T. Ishii, A. Takahasi, L. Furukawa, T. Asagami, T. Hino, F. Saito, Y. Otsuka, H. Kurumatani, F. Kobayashi, K. Kanmatsuse, and N. Kajiwara Kinins contribute to the improvement of insulin sensitivity during treatment with ACEI Hypertension 23 1994 450 455
211. 2 receptor- and tissue kallikrein-deficient mice Hypertension 40 2002 90 95
212. H. Trachtman Vitamin E prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells Microvasc. Res. 47 2 1994 232 239
213. H. Trachtman, S. Futterweit, and R.S. Bienkowski Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells Biochem. Biophys. Res. Commun. 191 2 1993 759 765
214. C. Tschöpe, T. Walther, M. Yu, A. Reinecke, M. Koch, C. Seligmann, S.B. Heringer, J.B. Pesquero, M. Bader, H. Schultheiss, and T. Unger Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes Immunopharmacology 44 1-2 1999 35 42
215. 1-receptor expression after myocardial infarction Br. J. Pharmacol. 129 8 2000 1537 1538
216. 1 receptor blockade J. Cardiovasc. Pharmacol. 39 2002 478 487
217. C. Tschöpe, U. Seidl, A. Reinecke, U. Riester, K. Graf, H.-P. Schultheiss, U. Hilgenfeldt, and T. Unger Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy Int. Immunopharmacol. 3 2003 335 344
218. 1 blockade after experimental myocardial infarction Cardiovasc. Res. 61 2004 559 569
219. C. Tschöpe, T. Walther, J. Koniger, F. Spillmann, D. Westermann, F. Escher, M. Pauschinger, J.B. Pesquero, M. Bader, H.P. Schultheiss, and M. Noutsias Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene FASEB J. 18 7 2004 828 835
220. Y. Tsutsumi, H. Matsubara, H. Masaki, H. Kurihara, S. Murasawa, S. Takai, M. Miyazaki, Y. Nozawa, R. Ozono, K. Nakagawa, T. Miwa, N. Kawada, Y. Mori, Y. Shibasaki, Y. Tanaka, S. Fujiyama, Y. Koyama, A. Fujiyama, H. Takahashi, and T. Iwasaka Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation J. Clin. Invest. 104 7 1999 925 935
221. A.J. Turner, S.R. Tipnis, J.L. Guy, G. Rice, and N.M. Hooper ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors Can. J. Physiol. Pharm. 80 4 2002 346 353
222. M. Uehara, H. Kishikawa, S. Isami, K. Kisanuki, Y. Ohkubo, N. Miyamura, T. Miyata, T. Yano, and M. Shichiri Effect of insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans Diabetologia 37 3 1994 300 307
223. 1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence Br. J. Pharmacol. 138 1 2003 13 22
224. 1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats FASEB J. 16 10 2002 1237 1241
225. C. Wang, L. Chao, and J. Chao Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats J. Clin. Invest. 95 1995 1710 1716
226. C.-H. Wang, N. Leung, N. Lapointe, L. Szeto, K.D. Uffelman, A. Giacca, J.L. Rouleau, and G.F. Lewis Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats Circulation 107 2003 1923 1929
227. M.P. Wautier, O. Chappey, S. Corda, D.M. Stern, A.M. Schmidt, and J.L. Wautier Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE Am. J. Physiol. Endocrinol. Metab. 280 5 2001 E685 E694
228. K.J. Way, N. Katai, and G.L. King Protein kinase C and the development of diabetic vascular complications Diabet. Med. 18 12 2001 945 959
229. G. Wiemer, L.W. Dobrucki, F.R. Louka, T. Malinski, and H. Heitsch AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium Hypertension 40 6 2002 847 852
230. A. Windebank, and E. Feldman Diabetes and the nervous system M. Aminoff Neurology and General Medicine 2001 Churchill Livingstone Philadelphia, PA 341 364
231. F.N. Witherow, A. Helmy, D.J. Webb, K.A.A. Fox, and D.E. Newby Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure Circulation 104 2001 2177 2181
232. W. Xiong, J. Chao, and L. Chao Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats Hypertension 25 4 Pt2 1995 715 719
233. C. Yang, and W.H. Hsu Glucose-dependency of bradykinin-induced insulin secretion from the perfused rat pancreas Regul. Pept. 71 1 1997 23 28
234. K. Yasunari, K. Maeda, T. Watanabe, M. Nakamura, A. Asada, and J. Yoshikawa Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation J. Cardiovasc. Pharmacol. 42 Suppl. 1 2003 S55 S60
235. K. Yayama, C. Wang, L. Chao, and J. Chao Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats Hypertension 31 1998 1104 1110
236. K. Yokota, M. Kishida, T. Ogura, J. Suzuki, F. Otsuka, Y. Mimura, M. Takeda, Y. Nakamura, and H. Makino Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension Hypertens. Res. 26 3 2003 265 272
237. I.V. Yosipiv, S. Dipp, and S.S. El-Dahr Targeted disruption of the bradykinin B(2) receptor gene in mice alters the ontogeny of the renin-angiotensin system Am. J. Physiol. Renal Physiol. 281 5 2001 F795 F801
238. C. Zhao, P. Wang, X. Xiao, J. Chao, L. Chao, D.W. Wang, and D.C. Zeldin Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats Hypertension 42 5 2003 1026 1033
239. X. Zhou, H. Ono, Y. Ono, and E.D. Frohlich Renoprotective effects of omapatrilat are mediated partially by bradykinin Am. J. Nephrol. 23 4 2003 214 221
240. P. Zimmet The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 29 4 Pt 2003 6S9 6S18
241. F.N. Ziyadeh, and D.C. Han Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephrology Kidney Int. 60 1997 S7 S11
242. A. Zuccollo, M. Navarro, G.M. Prendes, A. Dominguez, and O.L. Catanzaro Effects of HOE 140 on some renal functions in type I diabetic mice Arch. Physiol. Biochem. 104 2 1996 252 254
243. M.J. Zychma, J. Gumprecht, W. Trautsolt, I. Szydlowska, and W. Grzeszczak Polymorphic genes for kinin receptors, nephropathy and blood pressure in type 2 diabetic patients Am. J. Nephrol. 23 2003 112 116